Table 3 The side effects of solifenacin in group A and group C
From: Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder
Group A | Group C | |||
|---|---|---|---|---|
UI group n = 8 | Non-UI group n = 7 | UI group n = 8 | Non-UI group n = 7 | |
At 2 weeks | ||||
Dry mouth | 0 | 0 | 0 | 0 |
Constipation | 0 | 0 | 0 | 0 |
Blurred vision | 0 | 0 | 0 | 0 |
At 4 weeks | ||||
Dry mouth | 0 | 0 | 0 | 0 |
Constipation | 0 | 0 | 0 | 0 |
Blurred vision | 0 | 0 | 0 | 0 |
At 8 weeks | ||||
Dry mouth | 1 (12.5%) | 0 | 0 | 0 |
Constipation | 0 | 0 | 1 (12.5%) | 0 |
Blurred vision | 0 | 0 | 0 | 0 |
At 12 weeks | ||||
Dry mouth | 0 | 0 | 0 | 1 (14.3%) |
Constipation | 0 | 1 (14.3%) | 0 | 0 |
Blurred vision | 0 | 0 | 0 | 0 |